4-hydroxyphenylglycine, (s)-isomer profile

4-Hydroxyphenylglycine, (S)-isomer, also known as L-DOPA, is a naturally occurring amino acid that is a precursor to dopamine, a neurotransmitter involved in movement, mood, and cognition. It is used to treat Parkinson's disease by increasing dopamine levels in the brain. L-DOPA is synthesized from tyrosine, an amino acid found in proteins. It is typically administered orally, but can also be given intravenously. L-DOPA is effective in treating Parkinson's disease, but can cause side effects such as nausea, vomiting, and dyskinesia (involuntary movements). It is often used in combination with other medications, such as carbidopa, which helps to reduce side effects. L-DOPA is the most common treatment for Parkinson's disease and is widely studied to understand its mechanism of action and to develop new treatments for this condition.'

L-4-hydroxyphenylglycine : The L-enantiomer of 4-hydroxyphenylglycine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	36143
CHEMBL ID	1232077
CHEBI ID	31755
SCHEMBL ID	122315
MeSH ID	M0315049

Synonym
uk-25,842
CHEMBL1232077
4-hydroxyphenylglycine, (s)-
uk-25842
oxfenicine
(2s)-amino(4-hydroxyphenyl)ethanoic acid
CHEBI:31755 ,
l-4-hydroxyphenylglycine
32462-30-9
D05292
oxfenicine (usan/inn)
(2s)-amino(4-hydroxyphenyl)acetic acid
DB04291
(s)-(4-hydroxyphenyl)glycine
l-2-(p-hydroxyphenyl)glycine
NCGC00164509-01
uk 25842
4-hydroxy-l-phenylglycine, >=99.0% (nt)
(2s)-2-amino-2-(4-hydroxyphenyl)acetic acid
4-hydroxy-l-phenylglycine
BMSE000629
tox21_112144
cas-32462-30-9
dtxcid1026403
dtxsid3046403 ,
A821286
(2s)-2-amino-2-(4-hydroxyphenyl)acetic acid;l-p-hydroxyphenyglycine
(s)-amino-(4-hydroxyphenyl)acetic acid
(s)-(+)-2-amino-2-(4-hydroxyphenyl)acetic acid
l-(+)-2-(4-hydroxyphenyl)glycine
H1389
4-hydroxy-l-(+)-2-phenylglycine
l-(+)-a-4-hydroxyphenylglycine
(s)-alpha-amino-4-hydroxybenzeneacetic acid
(s)-2-amino-2-(4-hydroxyphenyl)essigsaeure
oxfenicinum [inn-latin]
p-hydroxy-l-phenylglycine
oxfenicina [inn-spanish]
benzeneacetic acid, alpha-amino-4-hydroxy-, (s)-
einecs 251-061-7
9yh0wh2z02 ,
oxfenicine [usan:inn:ban]
oxfenicina
oxfenicinum
benzeneacetic acid, alpha-amino-4-hydroxy-, (alphas)-
l-2-(4-hydroxyphenyl)glycine
unii-9yh0wh2z02
bdbm50403035
h-phg(4-oh)-oh
37784-25-1
l-p-hydroxyphenyglycine
oxfenicine [usan]
oxfenicine [inn]
amoxicillin sodium impurity i [ep impurity]
benzeneacetic acid, .alpha.-amino-4-hydroxy-, (s)-
SCHEMBL122315
LJCWONGJFPCTTL-ZETCQYMHSA-N
(s)-2-amino-2-(4-hydroxyphenyl)acetic acid
(s)-4-hydroxyphenylglycine
tox21_112144_1
NCGC00344518-01
AC-24628
mfcd00065932
J-018746
CS-W018812
HY-W018026
DS-11081
Q27095113
AKOS016842371
EN300-198950
Z1255364887
l-hydroxyphenylglycine

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
4-hydroxyphenylglycine	A glycine molecule carrying a 4-hydroxyphenyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GALC protein	Homo sapiens (human)	Potency	0.3162	28.1838	28.1838	28.1838	AID1159614
AR protein	Homo sapiens (human)	Potency	13.5321	0.0002	21.2231	8,912.5098	AID1259243; AID743040
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0003	23.4451	159.6830	AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1600	2.0300	3.9000	AID719674
Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)	IC50 (µMol)	100.0000	1.0500	1.0500	1.0500	AID719720
Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1259	4.2440	10.0000	AID719719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
long-chain fatty acid metabolic process	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
in utero embryonic development	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
L-cystine transport	Neutral amino acid transporter A	Homo sapiens (human)
amino acid transport	Neutral amino acid transporter A	Homo sapiens (human)
glutamine transport	Neutral amino acid transporter A	Homo sapiens (human)
L-alanine transport	Neutral amino acid transporter A	Homo sapiens (human)
L-cystine transport	Neutral amino acid transporter A	Homo sapiens (human)
proline transport	Neutral amino acid transporter A	Homo sapiens (human)
L-serine transport	Neutral amino acid transporter A	Homo sapiens (human)
threonine transport	Neutral amino acid transporter A	Homo sapiens (human)
hydroxyproline transport	Neutral amino acid transporter A	Homo sapiens (human)
synaptic transmission, glutamatergic	Neutral amino acid transporter A	Homo sapiens (human)
proline transmembrane transport	Neutral amino acid transporter A	Homo sapiens (human)
cognition	Neutral amino acid transporter A	Homo sapiens (human)
L-aspartate import across plasma membrane	Neutral amino acid transporter A	Homo sapiens (human)
transport across blood-brain barrier	Neutral amino acid transporter A	Homo sapiens (human)
chloride transmembrane transport	Neutral amino acid transporter A	Homo sapiens (human)
L-serine import across plasma membrane	Neutral amino acid transporter A	Homo sapiens (human)
L-alanine import across plasma membrane	Neutral amino acid transporter A	Homo sapiens (human)
L-glutamate transmembrane transport	Neutral amino acid transporter A	Homo sapiens (human)
response to hypoxia	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
long-chain fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
glucose metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
triglyceride metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to nutrient	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to xenobiotic stimulus	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
regulation of lipid storage	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to organic cyclic compound	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
epithelial cell differentiation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
positive regulation of fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
eating behavior	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to alkaloid	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
positive regulation of innate immune response	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to ethanol	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
aflatoxin metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
regulation of insulin secretion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
cellular response to fatty acid	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
liver regeneration	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
response to tetrachloromethane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
amino acid transport	Neutral amino acid transporter B(0)	Homo sapiens (human)
glutamine transport	Neutral amino acid transporter B(0)	Homo sapiens (human)
glutamine secretion	Neutral amino acid transporter B(0)	Homo sapiens (human)
neutral amino acid transport	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-serine transport	Neutral amino acid transporter B(0)	Homo sapiens (human)
erythrocyte differentiation	Neutral amino acid transporter B(0)	Homo sapiens (human)
symbiont entry into host cell	Neutral amino acid transporter B(0)	Homo sapiens (human)
protein homotrimerization	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-aspartate import across plasma membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
transport across blood-brain barrier	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-glutamine import across plasma membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
fatty acid metabolic process	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
fatty acid beta-oxidation	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
carnitine shuttle	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
carnitine metabolic process	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
response to blue light	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
long-chain fatty acid transport	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
protein binding	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
carnitine O-octanoyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
acyltransferase activity	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
L-cystine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
chloride channel activity	Neutral amino acid transporter A	Homo sapiens (human)
amino acid transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-alanine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-aspartate transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-cystine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-glutamine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-proline transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-serine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-threonine transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
symporter activity	Neutral amino acid transporter A	Homo sapiens (human)
L-hydroxyproline transmembrane transporter activity	Neutral amino acid transporter A	Homo sapiens (human)
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
protein-macromolecule adaptor activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
identical protein binding	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
palmitoleoyltransferase activity	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
virus receptor activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
protein binding	Neutral amino acid transporter B(0)	Homo sapiens (human)
amino acid transmembrane transporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-aspartate transmembrane transporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-glutamine transmembrane transporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
L-serine transmembrane transporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
symporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
antiporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
ligand-gated channel activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
signaling receptor activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
metal ion binding	Neutral amino acid transporter B(0)	Homo sapiens (human)
neutral L-amino acid transmembrane transporter activity	Neutral amino acid transporter B(0)	Homo sapiens (human)
carnitine O-palmitoyltransferase activity	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
protein binding	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoplasm	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
nucleolus	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 2, mitochondrial	Homo sapiens (human)
plasma membrane	Neutral amino acid transporter A	Homo sapiens (human)
centrosome	Neutral amino acid transporter A	Homo sapiens (human)
intermediate filament	Neutral amino acid transporter A	Homo sapiens (human)
plasma membrane	Neutral amino acid transporter A	Homo sapiens (human)
cell surface	Neutral amino acid transporter A	Homo sapiens (human)
membrane	Neutral amino acid transporter A	Homo sapiens (human)
melanosome	Neutral amino acid transporter A	Homo sapiens (human)
synapse	Neutral amino acid transporter A	Homo sapiens (human)
extracellular exosome	Neutral amino acid transporter A	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
mitochondrial outer membrane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
membrane	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, liver isoform	Homo sapiens (human)
plasma membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
basal plasma membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
melanosome	Neutral amino acid transporter B(0)	Homo sapiens (human)
extracellular exosome	Neutral amino acid transporter B(0)	Homo sapiens (human)
plasma membrane	Neutral amino acid transporter B(0)	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
mitochondrial outer membrane	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
mitochondrion	Carnitine O-palmitoyltransferase 1, muscle isoform	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay ID	Title	Year	Journal	Article
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID719672	Cytotoxicity in human KB cells	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719674	Inhibition of human CPT2	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719673	Inhibition of human FAO	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719719	Inhibition of human CPT1B	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719720	Inhibition of human CPT1A	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID719671	Inhibition of rat FAO	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	6 (60.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-hydroxyphenylglyoxylic acid 4-hydroxyphenylglyoxylic acid: RN given refers to parent cpd. 4-hydroxyphenylglyoxylate : Conjugate base of 4-hydroxyphenylglyoxylic acid.	2.06	1	phenols
2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid [no description available]	2.06	1
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.06	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	2.06	1	piperidines	cardiovascular drug
trimetazidine Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.	2.06	1	aromatic amine
ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate [no description available]	2.06	1
methyl 2-tetradecylglycidate methyl 2-tetradecylglycidate: structure	2.06	1
emeriamine emeriamine: derived from fungal metabolite emericedin; structure given in first source	2.06	1
etomoxir [no description available]	2.06	1	aromatic ether
4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate [no description available]	2.06	1
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid 4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.	2.06	1	4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid; gamma-lactone
b 807-27 [no description available]	2.06	1

Condition	Relationship Strength	Studies
Diabetes Mellitus, Adult-Onset [description not available]	2.06	1
Cardiac Failure [description not available]	2.06	1
Insulin Sensitivity [description not available]	2.06	1
Heart Disease, Ischemic [description not available]	2.06	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.06	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.06	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.06	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.06	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1

4-hydroxyphenylglycine, (s)-isomer

Description

Cross-References

Synonyms (72)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (50)

Molecular Functions (24)

Ceullar Components (14)

Bioassays (46)

Research

Studies (10)

Market Indicators

Research Demand Index: 12.15

Study Types

4-hydroxyphenylglycine, (s)-isomer

Description

Cross-References

Synonyms (72)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (50)

Molecular Functions (24)

Ceullar Components (14)

Bioassays (46)

Research

Studies (10)

Market Indicators

Research Demand Index: 12.15

Study Types

Related Drugs (12)

Related Conditions (11)